Company Overview of T2 Biosystems, Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications; T2Candida panel for identifying pathogens associated with sepsis; and T2MR Platform, a magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. It is also developing T2Stat, an integrated instrument that provi...
101 Hartwell Avenue
Lexington, MA 02421
Founded in 2006
Key Executives for T2 Biosystems, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $380.4K
Chief Operating Officer
Total Annual Compensation: $89.8K
Chief Medical Officer
Total Annual Compensation: $228.4K
Chief Scientific Officer
Total Annual Compensation: $274.3K
Compensation as of Fiscal Year 2014.
T2 Biosystems, Inc. Key Developments
T2 Biosystems, Inc. Announces Results from Data Analysis of the Company's T2Candida® Panel
Sep 16 15
T2 Biosystems, Inc. announced that results from a data analysis of the company's T2Candida® Panel for the detection and monitoring of Candida infection and sepsis were published in Future Microbiology. The publication compared aggregated results from T2Candida in the detection of invasive candidiasis and candidemia to blood culture, which included samples acquired from more than 1,900 patients. Out of 55 total cases, T2Candida demonstrated a 96.4% sensitivity (53 cases) compared to 60% (33 cases) with blood culture.
T2 Biosystems, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 02:55 PM
Sep 10 15
T2 Biosystems, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 02:55 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: John P. McDonough, Chief Executive Officer, President and Director.
T2 Biosystems Eyes Acquisitions
Sep 1 15
T2 Biosystems, Inc. (NasdaqGM:TTOO) is looking for acquisition opportunities. T2 Biosystems, Inc. has filed a Shelf Registration in the amount of $43 million. T2 Biosystems intend to use the net proceeds from the sale of the securities being offered by us for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include acquisition of companies or businesses, repayment and refinancing of debt, working capital, research and development expenditures, clinical trial expenditures, commercial expenditures and capital expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|